Scientists Uncover Cause of Rare Blood Clotting Issue, Pave Way for Safer COVID-19 Vaccines

Kathmandu – Scientists have identified the primary cause of the extremely rare blood clotting (blood clots) complications observed after some COVID-19 vaccinations. An international research team from Flinders University in Australia and the University of Greifswald in Germany has unraveled the molecular basis behind this mysterious condition which had puzzled experts for years. This breakthrough unlocks the potential for developing even safer vaccines in the future.

The study, focusing on misleading immune responses, revealed that the human immune system makes a critical error after adenovirus-based vaccination or natural infection. The issue arises because the body cannot distinguish between the viral protein and a protein found in blood called “platelet factor 4.” Following vaccination, while the immune system correctly attacks the virus, it mistakenly produces antibodies against its own blood proteins, triggering abnormal blood clotting. Although this reaction is exceptionally rare, it was previously reported in some individuals vaccinated with the AstraZeneca shot, a condition medically termed vaccine-induced immune thrombotic thrombocytopenia (VITT).

Dr. Jing Jing Wang, a researcher at Flinders University, explained that the team employed advanced technologies like mass spectrometry sequencing to detect similarities between the viral and blood proteins. She described this discovery as the “missing link” that scientifically explains how a normal immune response can cause harmful effects in very rare cases. Professor Tom Gordon, the team leader, hailed the finding as “an outstanding achievement of global collaboration.”

The most encouraging aspect is that vaccine developers can now eliminate this risk entirely by making minor modifications to the adenovirus protein structure. Scientists claim that altering the virus’s “pVII” protein will not affect vaccine efficacy but will completely prevent the blood clotting risk. Professor James McCluskey from the University of Melbourne called this a monumental scientific accomplishment that will play a crucial role in restoring public confidence in vaccines. This advancement is especially expected to assist the safe distribution of adenovirus-based vaccines in developing countries where they are widely used.